Cannabinoid Modulation of Cutaneous Aδ Nociceptors During Inflammation
- 1 November 2008
- journal article
- research article
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 100 (5) , 2794-2806
- https://doi.org/10.1152/jn.90809.2008
Abstract
Previous studies have demonstrated that locally administered cannabinoids attenuate allodynia and hyperalgesia through activation of peripheral cannabinoid receptors (CB1and CB2). However, it is currently unknown if cannabinoids alter the response properties of nociceptors. In the present study, correlative behavioral and in vivo electrophysiological studies were conducted to determine if peripheral administration of the cannabinoid receptor agonists arachidonyl-2′-chloroethylamide (ACEA) or (R)-(+)-methanandamide (methAEA) could attenuate mechanical allodynia and hyperalgesia, and decrease mechanically evoked responses of Aδ nociceptors. Twenty-four hours after intraplantar injection of complete Freund's adjuvant (CFA), rats exhibited allodynia (decrease in paw withdrawal threshold) and hyperalgesia (increase in paw withdrawal frequency), which were attenuated by both ACEA and methAEA. The antinociceptive effects of these cannabinoids were blocked by co-administration with the CB1receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophen yl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) but not with the CB2receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-y l](4-methoxyphenyl)methanone (AM630). ACEA and methAEA did not produce antinociception under control, non-inflamed conditions 24 h after intraplantar injection of saline. In parallel studies, recordings were made from cutaneous Aδ nociceptors from inflamed or control, non-inflamed skin. Both ACEA and methAEA decreased responses evoked by mechanical stimulation of Aδ nociceptors from inflamed skin but not from non-inflamed skin, and this decrease was blocked by administration of the CB1receptor antagonist AM251. These results suggest that attenuation of mechanically evoked responses of Aδ nociceptors contributes to the behavioral antinociception produced by activation of peripheral CB1receptors during inflammation.Keywords
This publication has 82 references indexed in Scilit:
- The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanismsBrain Research, 2008
- Cannabinoid CB2receptors: a therapeutic target for the treatment of inflammatory and neuropathic painBritish Journal of Pharmacology, 2008
- Peripheral cannabinoids attenuate carcinoma-induced nociception in miceNeuroscience Letters, 2008
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007
- Activation of peripheral cannabinoid CB1and CB2receptors suppresses the maintenance of inflammatory nociception: a comparative analysisBritish Journal of Pharmacology, 2007
- Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic painPain, 2006
- Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonistPAIN®, 2006
- Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic painNeuropharmacology, 2006
- AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brainLife Sciences, 1997
- AM630, a competitive cannabinoid receptor antagonistLife Sciences, 1995